Generess Fe is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 06, 2019. Details of Generess Fe's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6667050 | Chewable oral contraceptive |
Apr, 2019
(7 years ago) |
Expired
|
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(12 years ago) |
Expired
|
FDA has granted several exclusivities to Generess Fe. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Generess Fe, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Generess Fe.
Exclusivity Information
Generess Fe holds 1 exclusivities. All of its exclusivities have expired in 2013. Details of Generess Fe's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2013 |
US patents provide insights into the exclusivity only within the United States, but
Generess Fe is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Generess Fe's family patents as well as insights into
ongoing legal events
on those patents.
Generess Fe's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Generess Fe's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 06, 2019 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Generess Fe Generic API suppliers:
Ethinyl Estradiol; Norethindrone is the generic name for the brand Generess Fe. 18 different companies have already filed for the generic of Generess Fe, with Barr having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Generess Fe's generic
Alternative Brands for Generess Fe
There are several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone) as Generess Fe. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||
|---|---|---|---|---|---|---|
| Teva Branded Pharm |
| |||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |||||
|---|---|---|---|---|---|---|
| Apil |
| |||||
| Millicent Mfg Pr |
| |||||
| Teva Branded Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone, Generess Fe's active ingredient. Check the complete list of approved generic manufacturers for Generess Fe
About Generess Fe
Generess Fe is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. Generess Fe uses Ethinyl Estradiol; Norethindrone as an active ingredient. Generess Fe was launched by Teva in 2010.
Approval Date:
Generess Fe was approved by FDA for market use on 22 December, 2010.
Active Ingredient:
Generess Fe uses Ethinyl Estradiol; Norethindrone as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone ingredient
Dosage:
Generess Fe is available in tablet, chewable form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.025MG;0.8MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET, CHEWABLE | Discontinued | ORAL |
